



an Open Access Journal by MDPI

Virotherapy and Gene Therapy in Cancer

Guest Editor:

Dr. Bolni Marius Nagalo

Winthrop P. Rockefeller Cancer
Institute, University of Arkansas
for Medical Sciences, Little Rock,
AR, USA

Deadline for manuscript
submissions:

closed (15 May 2024)

Message from the Guest Editor

Recent advancements in oncolytic viral therapy and gene therapy for cancer have shown great potential for improving the survival rates and quality of life of cancer patients. We are excited to announce that our journal is currently accepting original research articles and reviews on a range of topics related to cancer treatment. We cordially invite you to submit your high-quality research articles on any of the following topics:

1. Oncolytic and immunomodulatory activity of live attenuated viral vaccines;
2. In situ vaccination of immunovirotherapy;
3. Radiation therapy combined with oncolytic viral therapy;
4. Oncolytic virus design and engineering;
5. Viral delivery of therapeutic proteins;
6. Cancer gene therapy;
7. Minimally invasive Cancer imaging using viral vectors;
8. Oncolytic virus delivery;
9. Systemic immunovirotherapy combined with immune checkpoint inhibitors;
10. Combination natural products and oncolytic viruses;
11. Targeting the stroma in Cancer;
12. Metastases targeting;
13. Combination therapies;
14. Combination of cellular therapy and oncolytic viral therapies.



mdpi.com/si/171929

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI